|
Agreements (Details) (USD $)
|
12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 1 Months Ended | 12 Months Ended | 84 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Nov. 30, 2009
Reliable Supply Agreement [Member]
|
Dec. 31, 2013
Reliable Supply Agreement [Member]
|
Dec. 31, 2012
Reliable Supply Agreement [Member]
|
Dec. 31, 2011
Reliable Supply Agreement [Member]
|
May 31, 2013
Nordion Supply Agreement [Member]
|
Dec. 31, 2013
Nordion Supply Agreement [Member]
|
Aug. 31, 2013
PETNET Supply Agreement [Member]
|
Dec. 31, 2013
PETNET Supply Agreement [Member]
|
Sep. 30, 2013
OsoBio Supply Agreement [Member]
|
Dec. 31, 2013
OsoBio Supply Agreement [Member]
|
Apr. 30, 2008
Research And Development Agreement [Member]
|
Jan. 31, 2002
Research And Development Agreement [Member]
|
Apr. 30, 2008
Research And Development Agreement [Member]
Minimum [Member]
|
Jan. 31, 2002
Research And Development Agreement [Member]
Minimum [Member]
|
Dec. 31, 2013
Employment Agreement [Member]
Minimum [Member]
|
Dec. 31, 2013
Employment Agreement [Member]
Maximum [Member]
|
Dec. 31, 2013
Astra Zeneca Agreement [Member]
|
Dec. 31, 2012
Astra Zeneca Agreement [Member]
|
Dec. 31, 2011
Astra Zeneca Agreement [Member]
|
Dec. 31, 2011
Astra Zeneca Agreement [Member]
Milestone Payments Based On Achievement Of Certain Clinical Development And Regulatory Filing Milestones [Member]
|
Dec. 31, 2012
Astra Zeneca Agreement [Member]
Milestone Payments Based On Achievement Of Certain Clinical Development And Regulatory Filing Milestones [Member]
|
Dec. 31, 2012
Astra Zeneca Agreement [Member]
Maximum [Member]
Milestone Payments Based On Receipt Of Certain Regulatory Approvals And Initiation Of Commercial Sales Of Licensed Product [Member]
|
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
|
Dec. 31, 2013
Alseres Pharmaceuticals Inc [Member]
|
Dec. 31, 2012
Alseres Pharmaceuticals Inc [Member]
|
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Alseres Milestone Payments Based On Product Registration Or Commercial Sales [Member]
|
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Milestone Payments Maximum [Member]
|
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Maximum [Member]
|
Dec. 31, 2012
Cardiosonix [Member]
|
Dec. 31, 2013
Cardiosonix [Member]
|
Dec. 31, 2013
Cardiosonix [Member]
Minimum [Member]
|
Dec. 31, 2013
Cardiosonix [Member]
Maximum [Member]
|
Dec. 31, 2013
Lymphoseek License Agreement [Member]
|
Dec. 31, 2012
Lymphoseek License Agreement [Member]
|
Dec. 31, 2011
Lymphoseek License Agreement [Member]
|
Dec. 31, 2013
Lymphoseek Expanded License Agreement [Member]
|
Dec. 31, 2012
Lymphoseek Expanded License Agreement [Member]
|
Dec. 31, 2011
Lymphoseek Expanded License Agreement [Member]
|
Jan. 31, 2006
Cira License Agreement [Member]
|
Dec. 31, 2013
Cira License Agreement [Member]
|
|
| Agreements [Line Items] | |||||||||||||||||||||||||||||||||||||||||||
| Purchases under manufacture and supply agreement | $ 666,000 | $ 939,000 | $ 544,000 | $ 771,000 | $ 1,400,000 | $ 1,200,000 | |||||||||||||||||||||||||||||||||||||
| Purchase orders issued | 0 | 314,000 | 1,400,000 | 0 | |||||||||||||||||||||||||||||||||||||||
| License fee | 25,000 | 25,000 | 5,000,000.0 | 5,000 | |||||||||||||||||||||||||||||||||||||||
| License maintenance fee | 25,000 | 25,000 | |||||||||||||||||||||||||||||||||||||||||
| Royalty on net sales of licensed products , percentage | 5.00% | 5.00% | 3.00% | 5.00% | |||||||||||||||||||||||||||||||||||||||
| Research and development | 23,710,183 | 16,890,482 | 15,154,365 | 5,000 | 14,000 | 5,000,000 | 366,000 | 1,800,000 | 273,000 | 33,000 | 98,000 | 29,000 | 31,000 | 28,000 | 100,000 | ||||||||||||||||||||||||||||
| Common stock, shares issued | 135,919,423 | 113,018,772 | 300,000 | 950,000 | 1,150,000.00 | ||||||||||||||||||||||||||||||||||||||
| Contingent milestone payment | 6,500,000.0 | 11,000,000.0 | 2,500,000 | 2,900,000 | |||||||||||||||||||||||||||||||||||||||
| Royalty percentage on grant revenues | 300.00% | ||||||||||||||||||||||||||||||||||||||||||
| Royalty expense | 25,000 | 25,000 | 84,000 | 100,000 | |||||||||||||||||||||||||||||||||||||||
| Percentage of sublicense fees (royalties) | 50.00% | 50.00% | |||||||||||||||||||||||||||||||||||||||||
| Accrued royalties | 0 | ||||||||||||||||||||||||||||||||||||||||||
| Maximum contingent liability | 3,100,000 | ||||||||||||||||||||||||||||||||||||||||||
| Ratio of entitled salary | 1.1 | 2.1 | |||||||||||||||||||||||||||||||||||||||||
| Sublicense execution payment, cash paid | 175,000 | ||||||||||||||||||||||||||||||||||||||||||
| Grants received from Office of the Chief Scientist | $ 775,000 | ||||||||||||||||||||||||||||||||||||||||||
| Initial Term | 3 years | 3 years | |||||||||||||||||||||||||||||||||||||||||
| Resolution Term | 60 days | 30 days | 30 days | 60 days | |||||||||||||||||||||||||||||||||||||||
| Automatic Renewal Date | 1 year | 2 years | |||||||||||||||||||||||||||||||||||||||||
| Notice Period | 180 days | 60 days | 12 months | ||||||||||||||||||||||||||||||||||||||||